Lithium

Lithium

SCHEMBL7181773

CCCCOc1ccc(PC(=O)c2c(Cl)cccc2OC)c(OCCCC)c1.[Li]

nearest known ligand 0.42

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.42
GAA P10253 1/20 0.42
KMT2A Q03164 1/20 0.42
MAPT P10636 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
THRB P10828 2/20 0.40
THRA P10827 1/20 0.40
DPP4 P27487 1/20 0.39
PPARA Q07869 3/20 0.39
PPARG P37231 2/20 0.39
PPARD Q03181 1/20 0.39
ELANE P08246 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
FAAH O00519 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
PTGES O14684 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Lithium SCHEMBL7180985 0.98 THRA (0.43) MEN1GAAKMT2AMAPTTDP1
SCHEMBL7181770 0.98 MEN1 (0.42) MEN1GAAKMT2AMAPTTDP1
SCHEMBL7180980 0.96 THRA (0.43) MEN1GAAKMT2AMAPTTDP1
Lithium SCHEMBL7189888 0.96 ELANE (0.42) MEN1GAAKMT2AMAPTTDP1
SCHEMBL7182731 0.95 THRA (0.44) MEN1GAAKMT2AMAPTTDP1
Lithium SCHEMBL7182893 0.94 FAAH (0.41) MEN1GAAKMT2ATDP1L3MBTL1
SCHEMBL7189884 0.94 ELANE (0.42) MEN1GAAKMT2AMAPTTDP1
Lithium SCHEMBL7174887 0.93 THRB (0.42) MEN1GAAKMT2AMAPTL3MBTL1
SCHEMBL7182885 0.92 FAAH (0.41) MEN1GAAKMT2ATDP1L3MBTL1
SCHEMBL7174883 0.91 THRB (0.42) MEN1GAAKMT2AMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MEN1 2312/4885GAA 4753/4885KMT2A 1586/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MEN1 2263/4885GAA 4793/4885KMT2A 956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.